- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00217854
Inflammatory Processes in the Airway of Asthmatics With Persistent Bronchial Hyperreactivity
Mechanisms of Airway Inflammation: Natural Exacerbation of Asthma Induced by Glucocorticoid Withdrawal
Study Overview
Detailed Description
BACKGROUND:
The Inhaled Glucocorticoid Withdrawal Protocol will investigate abnormalities in the asthmatic airway that occur in the setting of a "natural" endogenous exacerbation. It is known that chronic treatment with inhaled glucocorticoids causes a nearly complete disappearance of inflammatory cells from the airway and improvement in bronchial hyperreactivity, yet such patients have persistent bronchial hyperreactivity. Withdrawal of inhaled glucocorticoids causes a worsening of bronchial hyperreactivity. These observations suggest that a chronic derangement in the asthmatic airway might exist, which is unmasked by withdrawal of inhaled glucocorticoids and which reinitiates the inflammatory process. These "persistent" abnormalities in the asthmatic airway may be seen during quiescent stages of chronic asthma even when airway inflammatory changes are not evident. The abnormalities may be seen during the period of treatment with inhaled glucocorticoids or they may appear as one of the first signs after the withdrawal of inhaled glucocorticoids, thereby initiating the recurrence of asthma and promoting inflammation.
DESIGN NARRATIVE:
The purpose of this study is to examine inflammatory processes in the airway of moderate to severe persistent asthmatics who have persistent bronchial hyperreactivity despite chronic administration of inhaled glucocorticoids. Each participant will undergo bronchoscopic procedures and have assessment of bronchial hyperreactivity at the following two time points: 1) during treatment with inhaled fluticasone; and 2) after acute withdrawal of inhaled fluticasone.
The primary outcome of this study is the change in CD3 positive T cells in the airway submucosa.
The key secondary outcomes are as follows: 1) other inflammatory cell markers in the airway (e.g., CD4, CD8, CD68, CD45, EG2/MBP, tryptase, and neutrophil elastase); 2) RANTES (regulated on activation, normal T expressed and secreted) expression in airway; 3) FEV1 peak expiratory flows; 4) methacholine PC20; and 5) asthma symptom score.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Missouri
-
Saint Louis, Missouri, United States, 63110
- Washington University School of Medicine
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Symptoms of asthma as defined by the American Thoracic Society (ATS) definition. This includes the following:
- history of episodic shortness of breath (with or without associated wheezing) in association with reversible obstructive airways disease with at least a 20% decrement in FEV1 and FVC (from predicted values) that is documented at some time point by pulmonary function tests
- an improvement in expiratory flow rates of at least 15% of predicted values after inhalation of a beta-2 selective bronchodilator medication or other previous treatment (e.g. corticosteroids)
- The diagnosis may also be confirmed by an abnormal bronchospastic response to methacholine or exercise as described by Cherniak
- FEV1 greater than or equal to 70% of predicted value at time of study entry
- Regular use of inhaled corticosteroids at time of study entry (at least 400 mcg of Beclomethasone or equivalent)
Exclusion Criteria:
- Used inhaled cromolyn (Intal) or nedocromil (Tilade) in the month prior to study entry
- History of severe asthma requiring intubation
- Any cardiopulmonary or neurologic abnormality with which the risk of performing the procedure would outweigh the potential benefits (other than asthma)
- Upper respiratory tract infection or clinical evidence of a sinus infection during the month preceding the test
- History of cigarette smoking within the 5 years prior to study entry or greater than 10 pack-years total
- Pregnant or refuses to undergo urine pregnancy testing if female of child-bearing age (women of childbearing potential will not be challenged [methacholine challenge] unless they have had a menstrual period in the last 10 days or a negative pregnancy test within 2 weeks or are practicing adequate contraception)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Open label inhaled fluticasone
Patients are treated with open label high dose fluticasone for 30 days then discontinued.
Comparisons are pre- and post- treatment single arm.
|
Bronchoscopic procedure
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
change in CD3 positive T cells in the airway submucosa
Time Frame: Measured at Week 4
|
Measured at Week 4
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
inflammatory cell markers in the airway (CD4, CD8, CD68, CD45, EG2/MBP, tryptase, and neutrophil elastase)
Time Frame: Measured at Week 4
|
Measured at Week 4
|
RANTES expression in airway
Time Frame: Measured at Week 4
|
Measured at Week 4
|
FEV1, peak expiratory flows
Time Frame: Measured at Week 4
|
Measured at Week 4
|
methacholine PC20
Time Frame: Measured at Week 4
|
Measured at Week 4
|
asthma symptom score
Time Frame: Measured at Week 4
|
Measured at Week 4
|
Collaborators and Investigators
Collaborators
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 291
- P50HL056419 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Asthma
-
Vanderbilt University Medical CenterNot yet recruitingAsthma in Children | Asthma Attack | Asthma Acute | Acute Asthma Exacerbation | Asthma; StatusUnited States
-
University of California, San FranciscoCompletedAsthma in Children | Asthma Attack | Asthma Acute | Asthma ChronicUnited States
-
SingHealth PolyclinicsNot yet recruitingAsthma | Asthma in Children | Asthma Attack | Asthma Acute | Asthma Chronic
-
Johann Wolfgang Goethe University HospitalCompleted
-
Universita di VeronaCompleted
-
Parc de Salut MarActive, not recruitingAsthma in Children | Persistent Asthma | Asthma ExacerbationSpain
-
Forest LaboratoriesCompleted
-
Brunel UniversityKarolinska InstitutetUnknown
-
Value Outcomes Ltd.AstraZenecaCompletedAsthma, Bronchial | Bronchial Asthma | Asthma Chronic | Asthma; EosinophilicCzechia
Clinical Trials on Bronchoscopic
-
Broncus TechnologiesHeidelberg UniversityUnknown
-
Nordsjaellands HospitalCompleted
-
Medtronic - MITGCompletedCancer, Lung | Cancer, Metastatic to LungHong Kong, United Kingdom
-
Shanghai General Hospital, Shanghai Jiao Tong University...UnknownDiagnosis of Lung Complication After Allo-HSCT by Multiple Parameter System Through BAL (SHSYXY-BAL)Lung Infection | Bronchoalveolar Lavage Fluid
-
phenoMapper, LLCNIH/NCI - Grant award number: R01CA218357Recruiting
-
University Medical Center GroningenRecruitingPulmonary Nodules, SolitaryNetherlands
-
University Medical Center GroningenCompletedEmphysema | COPDNetherlands
-
Alexandria UniversityCompletedEndobronchial Mucosal Pathology in Pulmonary SarcoidosisEgypt
-
Shanghai Chest HospitalWest China Hospital; Beijing Chao Yang Hospital; Henan Provincial People's Hospital and other collaboratorsRecruitingPeripheral Pulmonary LesionChina
-
Uptake Medical Technology, Inc.CompletedLung Cancer | Non Small Cell Lung Cancer | Metastatic Lung CancerAustralia